REG - Avacta Group PLC - Notice of Results

AvactaAnnouncement

13/02/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200213:nRSM8226Ca

RNS Number : 8226C  Avacta Group PLC  13 February 2020

 

 
 
        13 February 2020
 

Avacta Group plc

("Avacta", the "Group" or the "Company")

 

Notice of Results

 

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and
reagents, will announce its financial results for the 17 months ended 31
December 2019 on Tuesday, 21 April 2020.

An analyst briefing given by Alastair Smith, Chief Executive Officer and Tony
Gardiner, Chief Financial Officer, will be held at 09.30 hrs on Tuesday, 21
April 2020 at finnCap's offices, 60 New Broad St, London EC2M 1JJ.

- Ends -

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                  Tel:  +44 (0)844 414 0452

 Alastair Smith, Chief Executive Officer           www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 finnCap Ltd (Nominated Adviser and Joint Broker)  Tel:  +44 (0)207 220 0500

 Geoff Nash / Giles Rolls - Corporate Finance      www.finncap.com (http://www.finncap.com)

 Tim Redfern - ECM

 Yellow Jersey PR (Financial Media and IR)         Tel: +44 (0)7764 947 137

 Sarah Hollins                                     Tel: +44 (0)7951 402 336

 Henry Wilkinson                                   avacta@yellowjerseypr.com (mailto:avacta@yellowjerseypr.com)

 Zyme Communications (Trade and Regional Media)    Tel: +44 (0)7787 502 947

 Katie Odgaard                                     katie.odgaard@zymecommunications.com
                                                   (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com)

Avacta is developing novel cancer immunotherapies combining its two
proprietary platforms - Affimer(®) biotherapeutics and pre|CISION™ tumour
targeted chemotherapy. With this approach, the Company aims to address the
lack of a durable response to current immunotherapies experienced by most
patients. The Company's therapeutics development activities are based in
Cambridge, UK.

 

The Company benefits from near-term revenues generated from Affimer reagents
for diagnostics, bioprocessing and research, through a separate business unit
based in Wetherby, UK.

 

The Affimer platform is an alternative to antibodies derived from a small
human protein. Despite their shortcomings, antibodies currently dominate
markets worth in excess of $100bn.  Affimer technology has been designed to
address many of these negative performance issues, principally: the time
taken, and the reliance on an animal's immune response, to generate new
antibodies; poor specificity in many cases; large size and cost.

 

Avacta's pre|CISION platform, activates chemotherapy only in the tumour,
thereby limiting systemic exposure and damage to healthy tissues, and thus
improving the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

By combining these two platforms the Company is building a wholly owned
pipeline of novel cancer therapies with the aim of creating effective
treatments for all cancer patients including those who do not respond to
existing immunotherapies. Avacta expects to take its first drug, a pre|CISION
targeted form of the standard-of-care Doxorubicin, into the clinic in the
middle of 2020.

 

Avacta has established drug development partnerships with pharma and biotech,
including with Moderna Therapeutics Inc., a collaboration with LG Chem to
develop treatments for autoimmune and inflammatory diseases worth up to $310m,
a partnership with ADC Therapeutics to develop Affimer drug conjugates and a
joint venture in South Korea with Daewoong Pharmaceuticals to develop the next
generation of stem cell therapies that incorporate Affimer immuno-modulators.
Avacta actively seeks to license its proprietary platforms in a range of
therapeutic areas.

 

The Avacta diagnostics business unit works with partners world-wide to develop
Affimers for evaluation by those third parties with the objective of
establishing royalty bearing license deals. The Company is also developing a
small in-house pipeline of Affimer-based diagnostic assays for licensing.

To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NORSFUFMEESSELE